D	C177536	GDC Property Terminology	C42761	Format	The organization of information according to preset specifications.	data_format	data format	
A	C177536	GDC Property Terminology	C171252	Electronic File Format	The structure of the information in an electronic file.	data_format	data format	
C	C177536	GDC Property Terminology	C17369	Imaging Procedure	Any technology or method that aids in the visualization of any biological process, cell, tissue or organ for use in screening, diagnosis, surgical procedures or therapy.	imaging_type	imaging type	
C	C177536	GDC Property Terminology	C175886	Scientific Data Type	The category of scientific data generated from an experiment or a study and/or recorded in a document or file.	data_category	data category	
C	C177536	GDC Property Terminology	C185250	Proportion of Duplicated Reads Data	Sequencing read quality control data detailing the relative proportion of duplicate reads that occurred during a nucleotide sequencing run. This can be calculated as the proportion of duplicate reads, divided by the total read count.	proportion_reads_duplicated	proportion reads duplicated	
C	C177536	GDC Property Terminology	C4809	Residual Disease	The persistence of tumor cells in the body following cancer treatment.	residual_disease	residual disease	
C	C177536	GDC Property Terminology	C49236	Therapeutic Procedure	Medical care intended to treat or cure a condition or lessen its symptoms. This includes the administration of drugs, surgical procedures, physical or psychotherapy, or the use of therapeutic devices.	treatment_or_therapy	treatment or therapy	
C	C177536	GDC Property Terminology	C50995	Disease Response	The molecular/pathological and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.	disease_response	disease response	
D	C177537	GDC Value Terminology	C147919	Ill-Defined Anatomic Site	An anatomic site that is not specified or defined well enough to associate with a specific site.	Other ill-defined sites | progression_or_recurrence_anatomic_site || Other ill-defined sites | site_of_resection_or_biopsy || Other ill-defined sites | tissue_or_organ_of_origin	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
D	C177537	GDC Value Terminology	C148157	HDAC Inhibitor CKD-581	A highly water-soluble, pan histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon administration, HDAC inhibitor CKD-581 targets and inhibits HDAC, resulting in an accumulation of highly acetylated histones, the induction of chromatin remodeling, and an altered pattern of gene expression. This leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which results in the inhibition of tumor cell division and the induction of tumor cell apoptosis. HDACs, upregulated in many tumor cell types, are a family of metalloenzymes responsible for the deacetylation of chromatin histone proteins.	HDAC Inhibitor CKD-581 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C159498	Imsapepimut	A second-generation peptide vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) with potential immunomodulating and antineoplastic activities. Vaccination with imsapepimut may activate the immune system to induce an immune response against IDO-expressing tumor cells. This may restore the proliferation and activation of various immune cells including cytotoxic T-lymphocytes (CTLs), natural killer cells (NKs), and dendritic cells (DCs), and may eradicate IDO-expressing tumor cells through a CTL-mediated response. IDO, a cytosolic enzyme responsible for tryptophan catabolism and conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs) and plays an important role in immunosuppression mainly through suppression of CTL activation.	IDO Peptide Vaccine IO102 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C33250	Palatine Tonsil	Two masses of lymphatic tissue located one on either side of the oropharynx in the oropharyngeal isthmus.	Tonsil, NOS | progression_or_recurrence_anatomic_site || Tonsil, NOS | site_of_resection_or_biopsy || Tonsil, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
D	C177537	GDC Value Terminology	C3688	Trabecular Adenoma	A benign epithelial neoplasm characterized by the presence of a trabecular glandular architectural pattern.	8190/0 | morphology || Trabecular adenoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
D	C177537	GDC Value Terminology	C3850	Pancreatic Carcinoma	A carcinoma arising from the exocrine pancreas. The overwhelming majority of pancreatic carcinomas are adenocarcinomas.	Pancreas Cancer | relationship_primary_diagnosis	C178243	relationship_primary_diagnosis
D	C177537	GDC Value Terminology	C4133	Tubular Adenoma	An adenoma arising from the glandular epithelium of the gastrointestinal tract. It is characterized by the presence of a tubular architectural pattern. Most often it occurs in the large intestine, small intestine, and the stomach. The neoplastic epithelial cells show dysplastic features.	8211/0 | morphology || Tubular adenoma, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
D	C177537	GDC Value Terminology	C4143	Tubulovillous Adenoma	An adenoma arising from the glandular epithelium of the gastrointestinal tract. It is characterized by the presence of a tubular and a villous architectural pattern. Most often it occurs in the large intestine, small intestine, and the stomach. The neoplastic epithelial cells show dysplastic features.	8263/0 | morphology || Papillotubular adenoma | primary_diagnosis || Tubulo-papillary adenoma | primary_diagnosis || Tubulovillous adenoma, NOS | primary_diagnosis || Villoglandular adenoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
D	C177537	GDC Value Terminology	C61599	Male Genitalia	The external male sexual organs.	Male genital organs, NOS | progression_or_recurrence_anatomic_site || Male genital organs, NOS | site_of_resection_or_biopsy || Male genital organs, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
D	C177537	GDC Value Terminology	C61600	Female Genitalia	The external female sexual organs.	Female genital tract, NOS | progression_or_recurrence_anatomic_site || Female genital tract, NOS | site_of_resection_or_biopsy || Female genital tract, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
D	C177537	GDC Value Terminology	C66845	Malignant Peripheral Nerve Sheath Tumor with Perineurial Differentiation	A very rare malignant tumor with morphologic features similar to those of benign perineurioma of soft tissue along with hypercellularity, nuclear atypia, hyperchromasia, and a high mitotic rate.	9571/3 | morphology || Perineural MPNST | primary_diagnosis || Perineurioma, malignant | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
D	C177537	GDC Value Terminology	C7399	Villous Adenoma	An adenoma arising from the glandular epithelium of the gastrointestinal tract. It is characterized by the presence of a villous architectural pattern. Most often it occurs in the large intestine, small intestine, and the stomach. The neoplastic epithelial cells show dysplastic features.	8261/0 | morphology || Villous adenoma, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
D	C177537	GDC Value Terminology	C7680	Adenocarcinoma In Situ in a Polyp	An adenocarcinoma arising in a polyp.	8210/2 | morphology || Adenocarcinoma in situ in a polyp, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
D	C177537	GDC Value Terminology	C7681	Carcinoma In Situ in a Polyp	An intraepithelial adenocarcinoma arising in a polyp.	8210/2 | morphology || Carcinoma in situ in a polyp, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C12402	Female Reproductive System	The collection of organs and tissues, including the ovaries, genital tract, and breasts, that have several functions, including sexual maturation, pregnancy, and childbirth.	Female genital tract, NOS | progression_or_recurrence_anatomic_site || Female genital tract, NOS | site_of_resection_or_biopsy || Female genital tract, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
A	C177537	GDC Value Terminology	C12722	Male Reproductive System	The sex organs of the male.	Male genital organs, NOS | progression_or_recurrence_anatomic_site || Male genital organs, NOS | site_of_resection_or_biopsy || Male genital organs, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
A	C177537	GDC Value Terminology	C156278	Cellular Neurothekeoma	A benign cutaneous neoplasm of uncertain differentiation that usually affects children and young adults and presents as a usually solitary well-circumscribed dermal nodule, predominantly in the face. It is a multilobulated neoplasm composed of nests of epithelioid cells with pale eosinophilic cytoplasm and vesicular nucleus. The nests of neoplastic cells are usually separated by collagenous or myxoid stroma.	9562/0 | morphology || Neurothekeoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C166499	Alteminostat	A highly water-soluble, pan histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon administration, alteminostat targets and inhibits HDAC, resulting in an accumulation of highly acetylated histones, the induction of chromatin remodeling, and an altered pattern of gene expression. This leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which results in the inhibition of tumor cell division and the induction of tumor cell apoptosis. HDACs, upregulated in many tumor cell types, are a family of metalloenzymes responsible for the deacetylation of chromatin histone proteins.	HDAC Inhibitor CKD-581 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C199060	Imsapepimut	A second-generation peptide vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) with potential immunomodulating and antineoplastic activities. Vaccination with imsapepimut may activate the immune system to induce an immune response against IDO-expressing tumor cells. This may restore the proliferation and activation of various immune cells including cytotoxic T-lymphocytes (CTLs), natural killer cells (NKs), and dendritic cells (DCs), and may eradicate IDO-expressing tumor cells through a CTL-mediated response. IDO, a cytosolic enzyme responsible for tryptophan catabolism and conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs) and plays an important role in immunosuppression mainly through suppression of CTL activation.	IDO Peptide Vaccine IO102 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C201127	Aleukemic Myeloid Leukemia	Myeloid leukemia presenting with leukemic infiltration of tissues and normal or decreased leukocyte count in the peripheral blood.	Aleukemic myelogenous leukemia | primary_diagnosis || Aleukemic myeloid leukemia | primary_diagnosis	C177621	primary_diagnosis
A	C177537	GDC Value Terminology	C201208	Border of Tongue	The peripheral edge of the tongue that delineates the tongue from adjacent structures in the oral cavity.	Border of tongue | progression_or_recurrence_anatomic_site || Border of tongue | site_of_resection_or_biopsy || Border of tongue | tissue_or_organ_of_origin	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
A	C177537	GDC Value Terminology	C201210	Ventral Surface of Tongue	The inferior surface of the tongue, which is adjacent to the floor of the mouth. It is attached to the floor of the mouth by the frenulum.	Ventral surface of tongue, NOS | progression_or_recurrence_anatomic_site || Ventral surface of tongue, NOS | site_of_resection_or_biopsy || Ventral surface of tongue, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
A	C177537	GDC Value Terminology	C201271	Anterior Floor of Mouth	The anterior aspect of the floor of the mouth.	Anterior floor of mouth | progression_or_recurrence_anatomic_site || Anterior floor of mouth | site_of_resection_or_biopsy || Anterior floor of mouth | tissue_or_organ_of_origin	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
A	C177537	GDC Value Terminology	C201272	Lateral Floor of Mouth	The lateral aspect of the floor of the mouth.	Anterior floor of mouth | progression_or_recurrence_anatomic_site || Anterior floor of mouth | site_of_resection_or_biopsy || Anterior floor of mouth | tissue_or_organ_of_origin	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
A	C177537	GDC Value Terminology	C201274	Anterior Two-Thirds of Tongue	The anterior two thirds of the tongue, roughly corresponding to the portion of the tongue anterior to the sulcus terminalis.	Anterior 2/3 of tongue, NOS | progression_or_recurrence_anatomic_site || Anterior 2/3 of tongue, NOS | site_of_resection_or_biopsy || Anterior 2/3 of tongue, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
A	C177537	GDC Value Terminology	C206392	Connective and Soft Tissue of Thorax	The connective and soft tissue of the part of the body lying between the neck and the abdomen.	Connective, subcutaneous and other soft tissues of thorax | progression_or_recurrence_anatomic_site || Connective, subcutaneous and other soft tissues of thorax | site_of_resection_or_biopsy || Connective, subcutaneous and other soft tissues of thorax | tissue_or_organ_of_origin	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
A	C177537	GDC Value Terminology	C206393	Peripheral Nerve of Head, Face, and Neck	A peripheral nerve that innervates the structures of head, face, and neck. This term refers to cranial nerves with the exceptions of the olfactory nerve and optic nerve.	Peripheral nerves and autonomic nervous system of head, face, and neck | progression_or_recurrence_anatomic_site || Peripheral nerves and autonomic nervous system of head, face, and neck | site_of_resection_or_biopsy || Peripheral nerves and autonomic nervous system of head, face, and neck | tissue_or_organ_of_origin	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
A	C177537	GDC Value Terminology	C206714	N2mi TNM Finding	A cancer TNM finding of regional lymph node metastasis indicating the presence of metastasis to para-aortic lymph nodes that is greater than 0.2 mm but not greater than 2.0 mm in diameter, with or without positive pelvic lymph nodes.	N2mi | ajcc_pathologic_n || N2mi | uicc_pathologic_n	C177612 || C188429	ajcc_pathologic_n || uicc_pathologic_n
A	C177537	GDC Value Terminology	C207066	Malignant Perineurioma	A morphologic subtype of perineurioma characterized by the presence of high mitotic activity, hypercellularity, hyperchromasia, and pleomorphism.	9571/3 | morphology || Perineural MPNST | primary_diagnosis || Perineurioma, malignant | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C207229	Pancreatic Carcinoma	A carcinoma that arises from the exocrine or endocrine pancreas. The vast majority of pancreatic carcinomas arise from the exocrine pancreas and are almost always adenocarcinomas. The main subtype of pancreatic adenocarcinoma is ductal adenocarcinoma, which is the most frequently seen type of pancreatic carcinoma. The carcinomas that arise from the endocrine pancreas (islet cells) are neuroendocrine carcinomas (small cell and large cell neuroendocrine carcinomas).	Pancreas Cancer | relationship_primary_diagnosis	C178243	relationship_primary_diagnosis
A	C177537	GDC Value Terminology	C208352	Acute Promyelocytic Leukemia	An acute myeloid leukemia characterized by the predominance of abnormal promyelocytes and translocations involving the retinoic acid receptor-α (RARA) gene. Over 95% of cases are characterized by the presence of the reciprocal balanced translocation t(15;17)(q24.1;q21.2) that results in the fusion of the promyelocytic leukemia (PML) gene and RARA gene. The remainder of the cases show variant RARA gene translocations with other genes including NUMA1, ZBTB16, STAT5B, and NPM1.	Acute promyelocytic leukemia, NOS | primary_diagnosis || FAB M3 (includes all variants) | primary_diagnosis || M3 | fab_morphology_code	C177621 || C91220	primary_diagnosis || fab_morphology_code
A	C177537	GDC Value Terminology	C209283	Tubular Adenoma	An adenoma characterized by the presence of a tubular architectural pattern. The vast majority of cases occur in the gastrointestinal tract.	8211/0 | morphology || Tubular adenoma, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C209284	Villous Adenoma	An adenoma characterized by the presence of a villous architectural pattern. The vast majority of cases occur in the gastrointestinal tract.	8261/0 | morphology || Villous adenoma, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C209285	Tubulovillous Adenoma	An adenoma characterized by the presence of a tubular and a villous architectural pattern. The vast majority of cases occur in the gastrointestinal tract.	8263/0 | morphology || Papillotubular adenoma | primary_diagnosis || Tubulo-papillary adenoma | primary_diagnosis || Tubulovillous adenoma, NOS | primary_diagnosis || Villoglandular adenoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C32482	Dorsum of Tongue	The superior, convex surface of the tongue, which is divided by the sulcus terminalis into anterior or oral (presulcal) and posterior or pharyngeal (postsulcal) parts. The mucosal membrane of the anterior two-thirds contain numerous varieties of papillae while the posterior one-third has no papillae and a cobblestone appearance due to underlying nodules of lymphoid tissue.	Dorsal surface of tongue, NOS | progression_or_recurrence_anatomic_site || Dorsal surface of tongue, NOS | site_of_resection_or_biopsy || Dorsal surface of tongue, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
A	C177537	GDC Value Terminology	C33291	Pelvic Girdle	The basin-shaped skeletal structure that is formed by the sacrum and the ilium, ischium, and pubis of each side that supports the trunk and to which the lower extremities attach.	Pelvic bones, sacrum, coccyx and associated joints | progression_or_recurrence_anatomic_site || Pelvic bones, sacrum, coccyx and associated joints | site_of_resection_or_biopsy || Pelvic bones, sacrum, coccyx and associated joints | tissue_or_organ_of_origin	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
A	C177537	GDC Value Terminology	C95902	Gastric Plexiform Fibromyxoma	A rare soft tissue neoplasm arising from the stomach.  It occurs in the antrum and pyloric region and it may extend into the duodenum.  It occurs in all ages and affects men and women equally.  Morphologically it is characterized by a multinodular plexiform mass that involves the muscular layer.  The neoplastic cells are spindle-shaped and the mitotic activity is low.  It follows a benign clinical course.	Plexiform fibromyxoma | primary_diagnosis	C177621	primary_diagnosis
C	C177537	GDC Value Terminology	C106256	Anti-FcRH5 Antibody-drug Conjugate DFRF4539A	An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FcRH5; CD307; FCRL5; IRTA2; BXMAS1) and conjugated to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, via the protease-labile linker maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (MC-VC-PABC), with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of anti-FcRH5 ADC DFRF4539A selectively binds to FcRH5 expressed on the surface of myeloma cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and tumor cell apoptosis. FcRH5, an immune receptor translocation-associated protein/Fc receptor homolog (IRTA/FCRH) family member and a B-cell lineage marker, is overexpressed on myeloma cells.	Antibody-Drug Conjugate DFRF4539A | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C118570	Anti-TROP-2 Antibody-drug Conjugate PF-06664178	An antibody-drug conjugate (ADC) composed of PF-06478924 (RN926), a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1), site-specifically conjugated via a valine-citrulline cleavable linker with the auristatin-based cytotoxic agent Aur0101 (PF-06380101), with potential antineoplastic activity. Upon administration of anti-TROP-2 ADC PF-06664178, the anti-TROP-2 monoclonal antibody moiety PF-06478924 targets and binds to TROP-2 expressed on tumor cells. Upon binding, internalization and linker cleavage, Aur0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of TROP-2-expressing tumor cells. TROP-2 is a transmembrane protein overexpressed in various tumors. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.	Antibody-drug Conjugate PF-06664178 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C120303	Anti-mesothelin Antibody-drug Conjugate BMS-986148	An antibody-drug conjugate (ADC) composed of a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein and tumor-associated antigen (TAA) mesothelin and conjugated, via a valine-citrulline linker, to the cytotoxic agent tubulysin, with potential antineoplastic activity. Upon administration of anti-mesothelin ADC BMS-986148, the monoclonal antibody moiety targets and binds to mesothelin. Upon internalization, the tubulysin moiety inhibits the polymerization of tubulin into microtubules. This leads to cell cycle arrest, induces tumor cell apoptosis, and may inhibit cellular proliferation of mesothelin-expressing tumor cells. Mesothelin is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue.	Anti-mesothelin Antibody-drug Conjugate BMS-986148 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C121802	Undifferentiated Sarcoma with Epithelioid Features	An undifferentiated soft tissue sarcoma characterized by the presence of a malignant cellular infiltrate with epithelioid morphology.	Undifferentiated epithelioid sarcoma | primary_diagnosis	C177621	primary_diagnosis
C	C177537	GDC Value Terminology	C12228	Base of Tongue	The posterior one third of the tongue behind the terminal sulcus that forms the anterior aspect of the oropharynx responsible for swallowing and modification of the voice in speech.	Base of tongue | primary_site || Base of tongue, NOS | progression_or_recurrence_anatomic_site || Base of tongue, NOS | site_of_resection_or_biopsy || Base of tongue, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || progression_or_recurrence_anatomic_site
C	C177537	GDC Value Terminology	C12284	Main Bronchus	One of two major branches of the trachea. Bifurcation of the trachea at the carina forms the left main bronchus and the right main bronchus.	Main bronchus | progression_or_recurrence_anatomic_site || Main bronchus | site_of_resection_or_biopsy || Main bronchus | tissue_or_organ_of_origin	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
C	C177537	GDC Value Terminology	C12285	Upper Lobe of the Lung	The upper-most lobe of either lung.	Upper lobe, lung | progression_or_recurrence_anatomic_site || Upper lobe, lung | site_of_resection_or_biopsy || Upper lobe, lung | sites_of_involvement || Upper lobe, lung | tissue_or_organ_of_origin	C156421 || C156422 || C173263 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || sites_of_involvement || progression_or_recurrence_anatomic_site
C	C177537	GDC Value Terminology	C123284	Anti-DLL3 Antibody-drug Conjugate SC-002	An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3), site-specifically conjugated to the cytotoxic pyrrolobenzodiazepine (PBD) dimer SC-DR002 via a plasma-stable valine-alanine dipeptide linker, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of anti-DLL3 ADC SC-002 targets and binds to DLL3 expressed on tumor cells. Upon binding and internalization, the dipeptide linker is cleaved upon cathepsin-mediated proteolysis and SC-DR002 is released. Then the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of DLL3-overexpressing tumor cells. DLL3, a membrane protein that binds to Notch receptors and regulates Notch-mediated signaling and gene transcription, is overexpressed by certain cancers but is rarely expressed by normal, healthy cells.	Antibody-drug Conjugate SC-002 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C12350	Spinal Meninges	Connective tissue membranes that surround and support the spinal cord and cauda equina. They are continuous with cerebral meninges, which surround and support the brain.	Spinal meninges | progression_or_recurrence_anatomic_site || Spinal meninges | site_of_resection_or_biopsy || Spinal meninges | tissue_or_organ_of_origin	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
C	C177537	GDC Value Terminology	C12465	Peripheral Nervous System	That part of the nervous system consisting of the nerves and neurons that reside or extend outside the central nervous system.	Peripheral nerves and autonomic nervous system | primary_site || Peripheral nervous system | sites_of_involvement	C158874 || C173263	primary_site || sites_of_involvement
C	C177537	GDC Value Terminology	C12689	Cauda Equina	The collection of spinal nerve roots, arising from lumbar pairs two through five, sacral pairs one through five, and the coccygeal nerve, that branch off the conus medullaris at the termination of the spinal cord, and float freely within the lumbar cistern before exiting the spinal column at the appropriate vertebra.	Cauda equina | progression_or_recurrence_anatomic_site || Cauda equina | site_of_resection_or_biopsy || Cauda equina | tissue_or_organ_of_origin	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
C	C177537	GDC Value Terminology	C12780	Reticuloendothelial System	A network of phagocytic cells, primarily monocytes and macrophages, located in the connective tissue of the bone marrow, spleen, and liver that are involved in the clearance of bacteria, toxins, exogenous antigens, and immune complexes from the blood and tissues, as well as cytotoxicity against tumor cells.	Reticuloendothelial system, NOS | progression_or_recurrence_anatomic_site || Reticuloendothelial system, NOS | site_of_resection_or_biopsy || Reticuloendothelial system, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
C	C177537	GDC Value Terminology	C12802	Tonsil	The two organs situated in the throat on either side of the narrow passage from the mouth to the pharynx. They are composed of lymphoid tissues.	Tonsil | biospecimen_anatomic_site || Tonsil | primary_site || Tonsil | sites_of_involvement || Tonsil | treatment_anatomic_sites || Tonsil, NOS | progression_or_recurrence_anatomic_site || Tonsil, NOS | site_of_resection_or_biopsy || Tonsil, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_sites
C	C177537	GDC Value Terminology	C12887	Renal Pelvis	The funnel-shaped proximal portion of the ureter located within the kidney into which urine is secreted from the collecting duct system of the kidney.	Renal pelvis | primary_site || Renal pelvis | progression_or_recurrence_anatomic_site || Renal pelvis | site_of_resection_or_biopsy || Renal pelvis | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || progression_or_recurrence_anatomic_site
C	C177537	GDC Value Terminology	C136807	Anti-CLDN6/9 Antibody-drug Conjugate SC-004	An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody directed against claudin-6 (CLDN6; CLDN-6) and claudin-9 (CLDN9; CLDN-9) linked to a cytotoxic pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of anti-CLDN6/9 ADC SC-004 targets and binds to CLDN6/9 expressed on tumor cells, and the PBD moiety is released. Then the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of CLDN6/9-overexpressing tumor cells. CLDN6, a transmembrane tight-junction protein and embryonic antigen, is overexpressed on a variety of tumor cells but is not expressed on normal, healthy adult cells. CLDN6 and CLDN9 differ at only 3 out of 76 residues in their extracellular loops, and CLDN9 is highly expressed in some normal tissues in addition to some tumors.	Antibody-drug Conjugate SC-004 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C142826	Anti-Caprin-1 Monoclonal Antibody TRK-950	A humanized monoclonal antibody directed against cell cycle associated protein 1 (cytoplasmic activation- and proliferation-associated protein 1; Caprin-1; CAPRIN1; RNA granule protein 105; RNG105), with potential antineoplastic activity. Upon administration, anti-Caprin-1 monoclonal antibody TRK-950 targets and binds to Caprin-1 expressed on tumor cells. This may induce antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thereby killing Caprin-1-expressing tumor cells. Caprin-1 is overexpressed on certain tumor cell types and plays a key role in tumor cell proliferation and metastasis.	Monoclonal Antibody TRK-950 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C148336	Other and Ill-Defined Sites ICD-O-3	Other anatomic sites that are referenced in topographic category C76 of ICD-O-3.	Other and ill-defined sites | primary_site || Other ill-defined sites | progression_or_recurrence_anatomic_site || Other ill-defined sites | site_of_resection_or_biopsy || Other ill-defined sites | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || progression_or_recurrence_anatomic_site
C	C177537	GDC Value Terminology	C153249	Binary Alignment Map	A binary representation of a sequence alignment map (SAM), a compact and indexable representation of nucleotide sequence alignments, compressed by the BGZF (Blocked GNU Zip Format) library.	BAM | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C153250	FASTQ Format	A text-based format for storing a biological sequence that encodes the nucleotide calls as well as their quality scores. It is an extension of the FASTA format.	FASTQ | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C156395	Toll-like Receptor 7/8 Agonist EIK1001	A toll-like receptor type 7 and 8 (TLR7/8) agonist, with potential immunostimulating and antineoplastic activities. Upon administration, TLR7/8 agonist EIK1001 targets, binds to and activates TLR7 and 8, thereby activating TLR7/8-mediated pathways. This stimulates the maturation and activation of antigen-presenting cells (APCs), including dendritic cells (DCs). Activation of DCs results in the production of pro-inflammatory cytokines, and the activation of cytotoxic T-lymphocyte (CTL)- and B-lymphocyte-mediated immune responses. This may lead to tumor cell lysis. TLR7 and 8, members of the TLR family, play fundamental roles in the activation of the innate immune system, myeloid cell responses and tumor antigen presentation.	TLR Agonist BDB001 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C158083	Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide	A preparation of ethylcellulose polymeric nanoparticles loaded with cetuximab, a recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR), and decorated with the somatostatin analog, octreotide, with potential antineoplastic activity. Upon oral administration, the octreotide moiety directs the nanoparticles, which remain inert until a pH of 6.8 is reached, to somatostatin receptors (SSTRs), which are present on the cell membranes of many neuroendocrine tumor (NET) cells. At this pH, cetuximab is selectively released from the ethylcellulose polymer. Cetuximab may then bind to the extracellular domain of EGFR-expressing tumor cells, thereby preventing the activation and subsequent dimerization of the receptor. This may inhibit signal transduction and inhibit tumor cell proliferation in EGFR-dependent tumor cells. EGFR, a member of the EGFR receptor tyrosine kinase family, may be overexpressed on the cell surfaces of various tumor types.	Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C160838	Absent Extranodal Tumor Extension	A finding that the extranodal tumor extension is absent.	No Extranodal Extension | extranodal_extension	C160837	extranodal_extension
C	C177537	GDC Value Terminology	C164049	Tab-Separated Value Format	A file format where each line in the file contains a single piece of data and where each field or value in a line of data is separated from the next by a tab character.	TSV | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C164050	Excel Open XML Format	A proprietary file format developed by Microsoft that allows the user to save a spreadsheet created in Excel in an open XML-format. The file then can be read and opened by other spreadsheet-compatible applications.	XLSX | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C164051	Methylation Beta Value	An estimate for the level of DNA methylation in a set of samples that is calculated as the ratio of average signal intensities for methylated alleles (M) divided by the average signal intensities of M plus unmethylated alleles (U), such that beta (b) equals M/(M+U). Beta values must fall between zero and one.	Methylation Beta Value | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C164317	Ilantimod	An orally available formulation containing a small molecule antagonist of the aryl hydrocarbon receptor (AhR; class E basic helix-loop-helix protein 76; bHLHe76) with potential immunomodulating and antineoplastic activities. Upon oral administration, ilantimod specifically binds to AhR, inhibits AhR activation, and prevents AhR-mediated signaling. Abrogation of AhR activation prevents the activation of immune-tolerant dendritic cells (DCs) and regulatory T-cells (Tregs) in the tumor microenvironment (TME). This may restore the immune response against tumor cells. AhR, a member of the basic helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) family of transcription factors, has important roles in regulating immunity and cellular differentiation. AhR can exhibit both pro-oncogenic and tumor suppressor-like functions depending on the tumor type; therefore, its expression may serve as a negative or positive prognostic factor.	Aryl Hydrocarbon Receptor Antagonist BAY2416964 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C167206	Dalutrafusp Alfa	A bifunctional fusion protein composed of a humanized aglycosylated immunoglobulin G1 kappa (IgG1k) antibody directed against the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), fused to the extracellular domain of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential immunomodulating and antineoplastic activities. Upon administration, dalutrafusp alfa targets and binds to both CD73 expressed on tumor cells and TGFbeta in the tumor microenvironment (TME). The binding of dalutrafusp alfa to CD73 prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine and the adenosine-mediated suppression of lymphocyte activity and trafficking. This increases the activity of cytotoxic T-lymphocytes (CTLs), activates macrophages and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. The binding of dalutrafusp alfa to TGFbeta neutralizes TGFbeta and prevents TGFbeta-mediated signaling. This abrogates TGFbeta-mediated immunosuppression in the TME, enhances immune cell infiltration and anti-tumor immunity in the TME, and promotes the CTL-mediated immune response against tumor cells leading to tumor cell death. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the TME. TGFbeta, overproduced in many types of cancer, plays a key role in immunosuppression in the TME, enhances tumor cell proliferation, and promotes cancer progression.	Bispecific Antibody GS-1423 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C168580	Xaluritamig	A humanized immunoglobulin G1 (IgG1) bispecific antibody directed against both the tumor-associated antigen (TAA) six transmembrane epithelial antigen of the prostate 1 (STEAP1) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, xaluritamig targets and binds to both STEAP1 expressed on the surface of tumor cells and CD3 expressed on T-cells. This results in the cross-linking of tumor cells and T-cells, and induces a cytotoxic T-lymphocyte (CTL) response against STEAP1-expressing tumor cells. STEAP1 is overexpressed in a variety of cancers including prostate cancer.	Bispecific Antibody AMG 509 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C172211	Sample and Data Relationship Format	A tab-delimited file describing the relationships between samples, arrays, data and other objects used or produced during a microarray experiment.	SDRF | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C172212	Investigation Description Format	A a tab-delimited containing information about an investigation, including its name, a description, the investigator's contact details, bibliographic references, and free text descriptions of any relevant protocols.	IDF | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C172213	Array Design Format	A tab-delimited file defining how each array in an investigation is used. This data includes what sequence is located at each position in an array and what the annotation of this sequence is; cross-references to entries in a public repository can be used if available.	ADF | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C172214	Spectral View Settings Format	An electronic file format based on TIFF that is used for storing multiple high-resolution images in a single electronic file.	SVS | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C172215	Mutation Annotation Format	A tab-delimited text file containing mutation information aggregated across a set of variant call files (VCF).	MAF | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C172216	Variant Call File Format	A text-based electronic file used for storing gene sequence variation data. The first text section is composed of a header containing the metadata and keywords used in the file. This is followed by the body of the file which is tab-separated into eight mandatory data columns for each sample. Additionally, the body of the file can include an unlimited number of optional columns to record other sample-related data.	VCF | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C17369	Imaging Procedure	Any technology or method that aids in the visualization of any biological process, cell, tissue or organ for use in screening, diagnosis, surgical procedures or therapy.	Imaging | method_of_diagnosis	C177576	method_of_diagnosis
C	C177537	GDC Value Terminology	C173707	Engineered Toxin Body Targeting CD38 MT-0169	An engineered toxin body (ETB) containing a single chain variable fragment (scFv) from an antibody targeting the cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38) that is fused to a cytotoxic payload composed of the enzymatically active, de-immunized, ribosome-inactivating cytotoxic payload Shiga-like toxin-A subunit (SLTA), with potential antineoplastic activity. Upon administration of ETB targeting CD38 MT-0169, the anti-CD38 scFv moiety specifically targets and binds to CD38-expressing tumor cells. Upon internalization, the SLTA moiety is released and acts as an N-glycosidase, which binds to and removes an adenine nucleobase from the 28S RNA component of the 60S ribosomal subunit of ribosomes. This irreversibly inhibits ribosome activity, which inhibits protein synthesis and leads to apoptosis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.	Engineered Toxin Body Targeting CD38 TAK-169 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C175460	Segigratinib	An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3) and colony stimulating factor 1 receptor (CSF1R; CSF-1R; CD115; M-CSFR), with potential immunomodulatory and antineoplastic activities. Upon administration, segigratinib binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-mediated signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. 3D185 also targets and binds to CSF1R, thereby blocking CSF1R activation and CSF1R-mediated signaling. This inhibits the activities of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), and prevents immune suppression in the tumor microenvironment (TME). This enhances antitumor T-cell immune responses and inhibits the proliferation of tumor cells. FGFR, a family of receptor tyrosine kinases (RTKs) upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival. CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor that plays major roles in tumor cell proliferation and metastasis.	FGFR/CSF-1R Inhibitor 3D185 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C17998	Unknown	Not known, observed, recorded; or reported as unknown by the data contributor.	Unknown | adapter_content || Unknown | adrenal_hormone || Unknown | adverse_event || Unknown | adverse_event_grade || Unknown | ajcc_clinical_m || Unknown | ajcc_clinical_n || Unknown | ajcc_clinical_stage || Unknown | ajcc_clinical_t || Unknown | ajcc_pathologic_m || Unknown | ajcc_pathologic_n || Unknown | ajcc_pathologic_stage || Unknown | ajcc_pathologic_t || Unknown | ajcc_staging_system_edition || Unknown | alcohol_frequency || Unknown | alcohol_history || Unknown | alcohol_intensity || Unknown | alcohol_type || Unknown | anaplasia_present || Unknown | anaplasia_present_type || Unknown | aneuploidy || Unknown | ann_arbor_b_symptoms || Unknown | ann_arbor_b_symptoms_described || Unknown | ann_arbor_clinical_stage || Unknown | ann_arbor_extranodal_involvement || Unknown | ann_arbor_pathologic_stage || Unknown | antigen || Unknown | asbestos_exposure_type || Unknown | barretts_esophagus_goblet_cells_present || Unknown | basic_statistics || Unknown | best_overall_response || Unknown | biospecimen_anatomic_site || Unknown | biospecimen_laterality || Unknown | biospecimen_type || Unknown | bone_marrow_malignant_cells || Unknown | burkitt_lymphoma_clinical_variant || Unknown | calgb_risk_group || Unknown | cancer_detection_method || Unknown | cause_of_death || Unknown | cause_of_death_source || Unknown | cdc_hiv_risk_factors || Unknown | chemical_exposure_type || Unknown | chemo_concurrent_to_radiation || Unknown | child_pugh_classification || Unknown | chipseq_antibody || Unknown | chipseq_target || Unknown | chromosomal_translocation || Unknown | chromosome || Unknown | chromosome_arm || Unknown | clark_level || Unknown | classification_of_tumor || Unknown | clonality || Unknown | cog_liver_stage || Unknown | cog_neuroblastoma_risk_group || Unknown | cog_renal_stage || Unknown | cog_rhabdomyosarcoma_risk_group || Unknown | columnar_mucosa_present || Unknown | comorbidities || Unknown | comorbidity_method_of_diagnosis || Unknown | consistent_pathology_review || Unknown | contiguous_organ_invaded || Unknown | country_of_birth || Unknown | country_of_residence_at_enrollment || Unknown | diabetes_treatment_type || Unknown | diagnosis_pathologically_confirmed || Unknown | disease_response || Unknown | disease_type || Unknown | distance_normal_to_tumor || Unknown | double_expressor_lymphoma || Unknown | double_hit_lymphoma || Unknown | drug_category || Unknown | dysplasia_degree || Unknown | dysplasia_type || Unknown | ecog_performance_status || Unknown | education_level || Unknown | eln_risk_classification || Unknown | embolic_agent || Unknown | enneking_msts_grade || Unknown | enneking_msts_metastasis || Unknown | enneking_msts_stage || Unknown | enneking_msts_tumor_site || Unknown | ensat_clinical_m || Unknown | ensat_pathologic_n || Unknown | ensat_pathologic_stage || Unknown | ensat_pathologic_t || Unknown | environmental_tobacco_smoke_exposure || Unknown | esophageal_columnar_dysplasia_degree || Unknown | esophageal_columnar_metaplasia_present || Unknown | ethnicity || Unknown | evidence_of_progression_type || Unknown | evidence_of_recurrence_type || Unknown | exposure_duration || Unknown | exposure_source || Unknown | exposure_type || Unknown | extracapsular_extension || Unknown | extracapsular_extension_present || Unknown | extranodal_extension || Unknown | extrathyroid_extension || Unknown | eye_color || Unknown | figo_stage || Unknown | first_event || Unknown | first_symptom_prior_to_diagnosis || Unknown | fragmentation_enzyme || Unknown | gastric_esophageal_junction_involvement || Unknown | gene_symbol || Unknown | gleason_grade_group || Unknown | gleason_grade_tertiary || Unknown | goblet_cells_columnar_mucosa_present || Unknown | haart_treatment_indicator || Unknown | hepatitis_sustained_virological_response || Unknown | histologic_progression_type || Unknown | histone_family || Unknown | histone_variant || Unknown | history_of_tumor || Unknown | history_of_tumor_type || Unknown | hormonal_contraceptive_type || Unknown | hormonal_contraceptive_use || Unknown | hormonal_replacement_therapy_status || Unknown | hormone_replacement_therapy_type || Unknown | hpv_strain || Unknown | hysterectomy_margins_involved || Unknown | hysterectomy_type || Unknown | igcccg_stage || Unknown | imaging_anatomic_site || Unknown | imaging_findings || Unknown | imaging_result || Unknown | imaging_type || Unknown | immunosuppressive_treatment_type || Unknown | initial_disease_status || Unknown | inpc_grade || Unknown | inpc_histologic_group || Unknown | inrg_stage || Unknown | inss_stage || Unknown | instrument_model || Unknown | international_prognostic_index || Unknown | irs_group || Unknown | irs_stage || Unknown | ishak_fibrosis_score || Unknown | iss_stage || Unknown | karnofsky_performance_status || Unknown | kmer_content || Unknown | laboratory_test || Unknown | largest_extrapelvic_peritoneal_focus || Unknown | laterality || Unknown | lost_to_followup || Unknown | lymph_node_dissection_site || Unknown | lymph_node_involved_site || Unknown | lymph_node_involvement || Unknown | lymph_nodes_removed || Unknown | lymphatic_invasion_present || Unknown | margin_status || Unknown | margins_involved_site || Unknown | marital_status || Unknown | masaoka_stage || Unknown | measurement_type || Unknown | measurement_unit || Unknown | medulloblastoma_molecular_classification || Unknown | melanoma_known_primary || Unknown | menopause_status || Unknown | metaplasia_present || Unknown | metastasis_at_diagnosis || Unknown | method_of_diagnosis || Unknown | method_of_sample_procurement || Unknown | micrometastasis_present || Unknown | micropapillary_features || Unknown | mismatch_repair_mutation || Unknown | mitosis_karyorrhexis_index || Unknown | molecular_analysis_method || Unknown | molecular_consequence || Unknown | morphologic_architectural_pattern || Unknown | morphology || Unknown | mutation_codon || Unknown | necrosis_present || Unknown | non_nodal_regional_disease || Unknown | non_nodal_tumor_deposits || Unknown | nononcologic_therapeutic_agents || Unknown | normal_tumor_genotype_snp_match || Unknown | number_of_pregnancies || Unknown | occupation_type || Unknown | ovarian_specimen_status || Unknown | ovarian_surface_involvement || Unknown | overrepresented_sequences || Unknown | oxygen_use_indicator || Unknown | oxygen_use_type || Unknown | parent_with_radiation_exposure || Unknown | pathogenicity || Unknown | per_base_n_content || Unknown | per_base_sequence_content || Unknown | per_base_sequence_quality || Unknown | per_sequence_gc_content || Unknown | per_sequence_quality_score || Unknown | per_tile_sequence_quality || Unknown | perineural_invasion_present || Unknown | peripancreatic_lymph_nodes_positive || Unknown | peritoneal_fluid_cytological_status || Unknown | peritoneal_washing_results || Unknown | ploidy || Unknown | prcc_type || Unknown | pregnancy_outcome || Unknown | pregnant_at_diagnosis || Unknown | premature_at_birth || Unknown | prescribed_dose_units || Unknown | preservation_method || Unknown | primary_diagnosis || Unknown | primary_gleason_grade || Unknown | primary_site || Unknown | prior_treatment || Unknown | procedures_performed || Unknown | progression_or_recurrence || Unknown | progression_or_recurrence_anatomic_site || Unknown | progression_or_recurrence_type || Unknown | protocol_identifier || Unknown | race || Unknown | radiosensitizing_agent || Unknown | reason_treatment_ended || Unknown | reason_treatment_not_given || Unknown | reflux_treatment_type || Unknown | relationship_primary_diagnosis || Unknown | relationship_type || Unknown | relative_deceased || Unknown | relative_smoker || Unknown | residual_disease || Unknown | residual_tumor || Unknown | residual_tumor_measurement || Unknown | rhabdoid_present || Unknown | risk_factor_method_of_diagnosis || Unknown | risk_factor_treatment || Unknown | risk_factors || Unknown | sarcomatoid_present || Unknown | satellite_nodule_present || Unknown | scan_tracer_used || Unknown | second_gene_symbol || Unknown | secondary_gleason_grade || Unknown | secondhand_smoke_as_child || Unknown | sequence_duplication_levels || Unknown | sequence_length_distribution || Unknown | site_of_resection_or_biopsy || Unknown | sites_of_involvement || Unknown | smoking_frequency || Unknown | specimen_type || Unknown | staining_intensity_scale || Unknown | staining_intensity_value || Unknown | supratentorial_localization || Unknown | synchronous_malignancy || Unknown | target_capture_kit || Unknown | test_analyte_type || Unknown | test_result || Unknown | test_units || Unknown | therapeutic_agents || Unknown | therapeutic_levels_achieved || Unknown | therapeutic_target_level || Unknown | time_between_waking_and_first_smoke || Unknown | timepoint_category || Unknown | tissue_or_organ_of_origin || Unknown | tissue_type || Unknown | tobacco_smoking_status || Unknown | transglottic_extension || Unknown | treatment_anatomic_sites || Unknown | treatment_dose_units || Unknown | treatment_effect || Unknown | treatment_effect_indicator || Unknown | treatment_emergent_adverse_event || Unknown | treatment_frequency || Unknown | treatment_intent_type || Unknown | treatment_outcome || Unknown | treatment_type || Unknown | tumor_confined_to_organ_of_origin || Unknown | tumor_depth_descriptor || Unknown | tumor_descriptor || Unknown | tumor_focality || Unknown | tumor_grade || Unknown | tumor_grade_category || Unknown | tumor_infiltrating_lymphocytes || Unknown | tumor_infiltrating_macrophages || Unknown | tumor_regression_grade || Unknown | tumor_shape || Unknown | type_of_smoke_exposure || Unknown | uicc_clinical_m || Unknown | uicc_clinical_n || Unknown | uicc_clinical_stage || Unknown | uicc_clinical_t || Unknown | uicc_pathologic_m || Unknown | uicc_pathologic_n || Unknown | uicc_pathologic_stage || Unknown | uicc_pathologic_t || Unknown | uicc_staging_system_edition || Unknown | ulceration_indicator || Unknown | undescended_testis_corrected || Unknown | undescended_testis_corrected_laterality || Unknown | undescended_testis_corrected_method || Unknown | undescended_testis_history || Unknown | undescended_testis_history_laterality || Unknown | variant_origin || Unknown | variant_type || Unknown | vascular_invasion_present || Unknown | vascular_invasion_type || Unknown | viral_hepatitis_serology_tests || Unknown | vital_status || Unknown | weiss_assessment_findings || Unknown | weiss_assessment_score || Unknown | wgs_coverage || Unknown | who_cns_grade || Unknown | who_nte_grade || Unknown | wilms_tumor_histologic_subtype || Unknown | zygosity || unknown | gender || unknown | prior_malignancy || unknown | progression_or_recurrence || unknown | relationship_gender || unknown | relative_with_cancer_history || unknown | treatment_or_therapy || unknown | vital_status	C102562 || C102704 || C104014 || C104015 || C104017 || C104018 || C104023 || C104027 || C105721 || C106304 || C106317 || C106541 || C106551 || C111073 || C112400 || C121007 || C123560 || C125738 || C125904 || C126378 || C127762 || C127768 || C127772 || C129439 || C13202 || C132299 || C133427 || C13355 || C133706 || C138899 || C139007 || C139577 || C140258 || C140259 || C140262 || C140266 || C141342 || C142346 || C143151 || C15256 || C154881 || C15599 || C156421 || C156422 || C157103 || C157110 || C157233 || C157410 || C157425 || C157437 || C158874 || C159229 || C159643 || C159824 || C160720 || C160827 || C160837 || C160996 || C16124 || C161320 || C16165 || C162221 || C164057 || C16457 || C164683 || C16515 || C16564 || C166199 || C166229 || C166276 || C16687 || C168796 || C17001 || C17049 || C17103 || C171253 || C17140 || C171435 || C173263 || C173544 || C17357 || C173595 || C17369 || C174459 || C175524 || C176287 || C176708 || C176985 || C177549 || C177550 || C177555 || C177556 || C177557 || C177558 || C177559 || C177561 || C177562 || C177564 || C177565 || C177566 || C177567 || C177568 || C177569 || C177570 || C177571 || C177572 || C177576 || C177577 || C177578 || C177579 || C177583 || C177585 || C177586 || C177587 || C177588 || C177589 || C177590 || C177591 || C177592 || C177593 || C177594 || C177595 || C177596 || C177597 || C177598 || C177599 || C177600 || C177601 || C177602 || C177603 || C177604 || C177605 || C177606 || C177607 || C177608 || C177609 || C177610 || C177611 || C177612 || C177613 || C177614 || C177616 || C177619 || C177620 || C177621 || C177622 || C177624 || C177626 || C177627 || C177628 || C177630 || C177631 || C177632 || C177633 || C177634 || C177635 || C177636 || C177637 || C177638 || C177640 || C177641 || C178243 || C178276 || C178286 || C178287 || C178288 || C178289 || C17953 || C181720 || C181723 || C182060 || C182097 || C182099 || C182101 || C182102 || C182109 || C182312 || C18304 || C185074 || C185264 || C185265 || C185266 || C185267 || C185268 || C185269 || C185270 || C185271 || C185272 || C185273 || C185274 || C185275 || C188000 || C188372 || C188373 || C188388 || C188406 || C188408 || C188409 || C188411 || C188415 || C188429 || C188446 || C188448 || C18849 || C18919 || C1909 || C19232 || C19697 || C19770 || C19796 || C198091 || C198092 || C198095 || C198101 || C198107 || C198127 || C198131 || C198139 || C198194 || C198195 || C198198 || C198200 || C198201 || C198204 || C198206 || C199145 || C200441 || C200442 || C200444 || C200446 || C200469 || C200470 || C200473 || C200474 || C200476 || C200477 || C20118 || C202137 || C202138 || C202139 || C202140 || C202155 || C202157 || C202158 || C202159 || C202160 || C206478 || C206479 || C206480 || C2480 || C25185 || C25188 || C25193 || C25218 || C25294 || C25717 || C268 || C28013 || C28076 || C2873 || C29878 || C2991 || C33027 || C3420 || C35529 || C35886 || C36037 || C36292 || C38032 || C39694 || C4086 || C41331 || C42578 || C43283 || C45824 || C45902 || C4809 || C48603 || C48604 || C48605 || C49236 || C50995 || C54398 || C574 || C67415 || C70700 || C70713 || C70729 || C81180 || C81229 || C81239 || C83280 || C83315 || C83393 || C85416 || C89081 || C90491 || C92808 || C93431 || C93711 || C94536 || C94811 || C95149 || C97229 || C97926 || C99532	inpc_grade || reason_treatment_not_given || weiss_assessment_score || weiss_assessment_findings || ensat_pathologic_stage || ensat_pathologic_t || ensat_pathologic_n || ensat_clinical_m || ecog_performance_status || tumor_regression_grade || mitosis_karyorrhexis_index || menopause_status || number_of_pregnancies || igcccg_stage || premature_at_birth || child_pugh_classification || margin_status || figo_stage || double_hit_lymphoma || alcohol_intensity || staining_intensity_value || perineural_invasion_present || vascular_invasion_present || medulloblastoma_molecular_classification || chromosome || protocol_identifier || inrg_stage || chromosome_arm || mismatch_repair_mutation || double_expressor_lymphoma || iss_stage || residual_tumor || enneking_msts_stage || enneking_msts_grade || enneking_msts_tumor_site || enneking_msts_metastasis || chemo_concurrent_to_radiation || gleason_grade_group || masaoka_stage || hysterectomy_type || ulceration_indicator || hormone_replacement_therapy_type || site_of_resection_or_biopsy || tissue_or_organ_of_origin || exposure_type || hpv_strain || first_symptom_prior_to_diagnosis || hormonal_contraceptive_use || tumor_focality || eye_color || primary_site || calgb_risk_group || lymph_nodes_removed || lost_to_followup || lymphatic_invasion_present || satellite_nodule_present || extranodal_extension || transglottic_extension || prior_treatment || synchronous_malignancy || haart_treatment_indicator || metastasis_at_diagnosis || type_of_smoke_exposure || comorbidities || treatment_emergent_adverse_event || fragmentation_enzyme || ethnicity || treatment_dose_units || tumor_descriptor || reason_treatment_ended || histone_family || pathogenicity || ploidy || race || risk_factors || second_gene_symbol || environmental_tobacco_smoke_exposure || biospecimen_anatomic_site || sites_of_involvement || variant_type || gender || gene_symbol || imaging_type || classification_of_tumor || peritoneal_fluid_cytological_status || cause_of_death_source || imaging_result || morphology || irs_group || irs_stage || ajcc_clinical_stage || ajcc_pathologic_stage || test_analyte_type || ann_arbor_clinical_stage || ann_arbor_pathologic_stage || ajcc_staging_system_edition || eln_risk_classification || comorbidity_method_of_diagnosis || inpc_histologic_group || who_cns_grade || who_nte_grade || wilms_tumor_histologic_subtype || margins_involved_site || progression_or_recurrence_anatomic_site || supratentorial_localization || distance_normal_to_tumor || method_of_diagnosis || evidence_of_recurrence_type || dysplasia_degree || country_of_residence_at_enrollment || target_capture_kit || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || burkitt_lymphoma_clinical_variant || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || hysterectomy_margins_involved || metaplasia_present || necrosis_present || non_nodal_regional_disease || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || ovarian_surface_involvement || progression_or_recurrence || rhabdoid_present || risk_factor_treatment || variant_origin || biospecimen_laterality || ajcc_clinical_m || ajcc_pathologic_m || ovarian_specimen_status || viral_hepatitis_serology_tests || instrument_model || ajcc_clinical_n || ajcc_pathologic_n || chipseq_antibody || chipseq_target || initial_disease_status || pregnant_at_diagnosis || histone_variant || primary_diagnosis || relationship_gender || cdc_hiv_risk_factors || secondhand_smoke_as_child || smoking_frequency || time_between_waking_and_first_smoke || cog_liver_stage || cog_neuroblastoma_risk_group || cog_renal_stage || cog_rhabdomyosarcoma_risk_group || hepatitis_sustained_virological_response || ajcc_clinical_t || ajcc_pathologic_t || reflux_treatment_type || treatment_effect_indicator || progression_or_recurrence_type || esophageal_columnar_dysplasia_degree || relationship_primary_diagnosis || peripancreatic_lymph_nodes_positive || anaplasia_present || anaplasia_present_type || vascular_invasion_type || largest_extrapelvic_peritoneal_focus || education_level || consistent_pathology_review || undescended_testis_corrected_laterality || parent_with_radiation_exposure || undescended_testis_corrected || undescended_testis_history || undescended_testis_corrected_method || undescended_testis_history_laterality || adrenal_hormone || imaging_anatomic_site || clonality || history_of_tumor_type || adapter_content || basic_statistics || kmer_content || overrepresented_sequences || per_base_n_content || per_base_sequence_content || per_base_sequence_quality || per_sequence_gc_content || per_sequence_quality_score || per_tile_sequence_quality || sequence_duplication_levels || sequence_length_distribution || alcohol_frequency || exposure_source || asbestos_exposure_type || drug_category || uicc_clinical_m || uicc_clinical_n || uicc_clinical_stage || uicc_clinical_t || uicc_pathologic_m || uicc_pathologic_n || uicc_pathologic_stage || uicc_pathologic_t || history_of_tumor || prior_malignancy || treatment_outcome || therapeutic_agents || preservation_method || tissue_type || molecular_analysis_method || tobacco_smoking_status || cancer_detection_method || chemical_exposure_type || evidence_of_progression_type || extracapsular_extension || first_event || lymph_node_dissection_site || mutation_codon || peritoneal_washing_results || residual_tumor_measurement || risk_factor_method_of_diagnosis || therapeutic_levels_achieved || therapeutic_target_level || timepoint_category || tumor_grade_category || uicc_staging_system_edition || imaging_findings || country_of_birth || contiguous_organ_invaded || measurement_type || melanoma_known_primary || relative_smoker || wgs_coverage || tumor_depth_descriptor || tumor_shape || tumor_infiltrating_lymphocytes || tumor_infiltrating_macrophages || international_prognostic_index || extracapsular_extension_present || extrathyroid_extension || histologic_progression_type || micrometastasis_present || nononcologic_therapeutic_agents || oxygen_use_indicator || oxygen_use_type || radiosensitizing_agent || staining_intensity_scale || prescribed_dose_units || hormonal_replacement_therapy_status || prcc_type || scan_tracer_used || laterality || marital_status || occupation_type || treatment_type || laboratory_test || vital_status || antigen || karnofsky_performance_status || tumor_grade || aneuploidy || relative_with_cancer_history || disease_type || lymph_node_involved_site || chromosomal_lymph_node_involvement || morphologic_architectural_pattern || tumor_confined_to_organ_of_origin || test_result || treatment_effect || sarcomatoid_present || dysplasia_type || adverse_event || measurement_unit || ann_arbor_b_symptoms_described || zygosity || alcohol_type || residual_disease || primary_gleason_grade || secondary_gleason_grade || gleason_grade_tertiary || treatment_or_therapy || disease_response || treatment_intent_type || immunosuppressive_treatment_type || test_units || method_of_sample_procurement || specimen_type || treatment_anatomic_sites || relative_deceased || alcohol_history || cause_of_death || exposure_duration || biospecimen_type || relationship_type || inss_stage || treatment_frequency || pregnancy_outcome || hormonal_contraceptive_type || procedures_performed || adverse_event_grade || best_overall_response || clark_level || ishak_fibrosis_score || embolic_agent || molecular_consequence || diabetes_treatment_type
C	C177537	GDC Value Terminology	C182456	Comma Separated Values Format	A text file format that separates data elements with commas.	CSV | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C184741	Aggregated Somatic Variation Data	Sequence variation data from non-germline cell or tissue samples that has been aggregated across samples, sequencing runs and/or multiple variant callers.	Aggregated Somatic Mutation | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C184745	Allele-Specific Copy Number Segment Data	Nucleotide sequence data where repeated sequences have been segmented into genomic regions to allow the calculation of estimated copy number of alleles for each region.	Allele-Specific Copy Number Segment | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C184749	BEDPE Format	A text file format used to store genomic paired-end sequencing data that includes coordinates and associated metadata.	BEDPE | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C184752	Cohort Level Copy Number Scores	A set of derived sequence copy number data values grouped according to study-specific categories.	Cohort Level Copy Number Scores | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C184759	Gene Level Copy Number Scores	A set of derived sequence copy number data values grouped by genetic location.	Gene Level Copy Number Scores | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C184761	Genome Variation Format	A tab-delimited nine-column file to describe nucleotide sequence variation data. The Genome Variation Format (GVF) is based on the Generic Feature Format Version 3 (GFF3) but the GVF specifies additional text format constraints and allows for additional attributes.	GVF | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C184762	IDAT Format	A proprietary, encrypted XML-based, compressed electronic file format from Illumina Inc. for storing genome-wide profiling data. The data contains a summary of the intensity data generated from each probe used during a sequencing run.	IDAT | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C184763	Hierarchical Data Format 5	A hierarchical, filesystem-like data format that can store metadata in the form of user-defined, named attributes, which are attached to groups and datasets, and representations of images and tables built up using datasets, groups and attributes.	HDF5 | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C184768	JPEG 2000 Format	A discrete wavelet transform (DWT)-based compression standard electronic file format for storing video images.	JPEG 2000 | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C184769	JSON Format	A common open standard file format and data interchange format that uses human-readable text consisting of attribute-value pairs and arrays to store and transmit data.	JSON | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C184774	Masked Intensity Sequencing Data	Sequencing chromatogram data where potential germline and low-quality base calls have been masked.	Masked Intensities | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C184775	Masked Annotated Somatic Variation Data	Annotated nucleotide sequence variation data where potential germline and low-quality base calls have been masked.	Masked Annotated Somatic Mutation | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C184776	Masked Copy Number Segment Data	Segmented sequence copy number data where probes associated frequently with germline variants have been masked prior to data analysis.	Masked Copy Number Segment | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C184777	Masked Somatic Variation Data	Nucleotide sequence variation data where potential germline and low-quality base calls have been masked.	Masked Somatic Mutation | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C184778	MEX Format	A minimal base ASCII file format to facilitate the exchange of data matrices.	MEX | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C184793	Raw Intensity Sequencing Data	The nucleotide sequencing chromatogram generated by the sequencing instrument that has not been subjected to any normalization, alignment or other data processing steps.	Raw Intensities | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C184795	Raw Somatic Variation Data	Unfiltered, unannotated somatic variant caller data.	Raw Simple Somatic Mutation | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C184804	SRA-XML Format	An XML-based electronic file format used by the NCBI Sequence Read Archive (SRA) and the European Nucleotide Archive (ENA) to store raw sequencing data from next generation sequencing platforms and any corresponding sequence analysis data and associated metadata for the study, sample and experiment.	SRA XML | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C184805	TARGZ Format	An electronic file containing multiple files archived using the Unix-based tape archive (tar) utility and then compressed with the GNU zip (gzip) utility.	TARGZ | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C184806	TBI Format	A tab-delimited file that contains an index for the genome positions in a compressed (zipped) variant call format file.	TBI | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C190163	BAI File	An index file associated with a binary alignment map (BAM) file, a compressed binary version of a sequence alignment/map (SAM) file.	BAI | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C190164	BCR Biotab Format	Files that consist of aggregate clinical and biospecimen data across all cases of the given project. Biotab files are supplemental files that are available in the Genomic Data Commons (GDC) Legacy Archive as tab-delimited files on a project level basis. These may also include fields that are not available in the GDC application programming interface (API).	BCR Biotab | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C190189	TAR Format	A file format generated by the Unix command-line utility tar (tape archive). It is used for collecting many files into one archive file.	TAR | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C191737	Affymetrix CEL Format	A type of file that stores the results of intensity calculations of pixel values for DNA microarray image analysis. The data includes an intensity value, standard deviation of the intensity, the number of pixels used to calculate the intensity value, a flag to indicate an outlier as calculated by the algorithm, and a user defined flag indicating whether the feature should be excluded from future analysis. The file also stores the previously stated data for each feature on the probe array.	CEL | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C203250	Neuroendocrine Tumor G1	A well-differentiated, low-grade epithelial neoplasm with neuroendocrine differentiation. It arises from multiple sites, including the digestive system, lung, and head and neck.	G1 | who_nte_grade || Neuroendocrine tumor, grade 1 | primary_diagnosis	C177567 || C177621	who_nte_grade || primary_diagnosis
C	C177537	GDC Value Terminology	C204352	Genomic Variant Call Format	A text file format used for storing gene sequence variations. It is a type of variant call format that has a record for all sites, whether there is a variant call there or not. The format includes metrics of the confidence that positions are actually non-variant vs. a factor of minimum read-depth and genotype quality.	gVCF | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C27031	Pancreatic Neuroendocrine Neoplasm	A neoplasm with neuroendocrine differentiation that arises from the islet cells of the pancreas. It includes neuroendocrine tumors and neuroendocrine carcinomas.	8150/1 | morphology || Islet cell tumor, NOS | primary_diagnosis || Pancreatic endocrine tumor, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C27252	Enterochromaffin-Like Cell Neuroendocrine Tumor G1	A well-differentiated, low-grade neuroendocrine neoplasm (carcinoid tumor) arising from the gastrointestinal tract. It is characterized by the presence of enterochromaffin-like type granules in the neoplastic cells.	8242/1 | morphology || 8242/3 | morphology || ECL cell carcinoid, NOS | primary_diagnosis || ECL cell carcinoid, malignant | primary_diagnosis || Enterochromaffin-like cell carcinoid, NOS | primary_diagnosis || Enterochromaffin-like cell tumor, malignant | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C27388	Hepatocellular Scirrhous Carcinoma	An uncommon type of hepatocelluar carcinoma, morphologically characterized by significant fibrosis around the sinusoid-like spaces and atrophy of the tumor trabeculae.	8172/3 | morphology || Hepatocellular carcinoma, scirrhous | primary_diagnosis || Sclerosing hepatic carcinoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C27720	Pancreatic Neuroendocrine Tumor	A well-differentiated, low-, intermediate-, or high-grade neoplasm with neuroendocrine differentiation that arises from the islet cells of the pancreas. According to the presence or absence of clinical syndromes that result from hormone hypersecretion, pancreatic neuroendocrine tumors are classified either as functional or nonfunctional.	8150/0 | morphology || Pancreatic endocrine tumor, benign | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C2854	Warthin Tumor	A benign tumor that arises from the salivary gland and is characterized by the presence of an oncocytic, often papillary epithelial component, dense lymphoid stroma, and cystic spaces. It occurs primarily in the parotid gland and is the second most common benign parotid gland tumor (after pleomorphic adenoma). A strong association with smoking has been reported. It typically presents as a painless swelling in the lower portion of the parotid gland.	8561/0 | morphology || Adenolymphoma | primary_diagnosis || Papillary cystadenoma lymphomatosum | primary_diagnosis || Warthin tumor | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C2855	Adenoma	A neoplasm that arises from the glandular epithelium. It may be encapsulated or non-encapsulated. The neoplastic glandular epithelial cells may or may not display cellular atypia or dysplasia. Representative examples include gastrointestinal tract adenomas, thyroid gland follicular adenomas, and pituitary neuroendocrine tumors/adenomas. The vast majority are benign.	8140/0 | morphology || Adenoma, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3182	Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA	An acute promyelocytic leukemia characterized by the reciprocal balanced translocation t(15;17)(q24.1;q21.2) that results in the fusion of the promyelocytic leukemia (PML) gene and retinoic acid receptor-α (RARA) gene. The t(15;17)(q24.1;q21.2) with the resulting PML-RARA fusion gene occurs in over 95% of cases of acute promyelocytic leukemia. The remainder of the cases show variant RARA gene translocations with other genes.	9866/3 | morphology || Acute myeloid leukemia, PML/RAR-alpha | primary_diagnosis || Acute promyelocytic leukaemia, PML-RAR-alpha | primary_diagnosis || Acute promyelocytic leukaemia, t(15;17)(q22;q11-12) | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3296	Osteoma	A benign, well-circumscribed bone-forming neoplasm predominantly composed of lamellar bone. It usually arises from the calvarial, facial, or jaw bones.  It is usually asymptomatic but it may cause local swelling or obstruction of the paranasal sinuses.  Asymptomatic cases have an indolent clinical course.	9180/0 | morphology || Osteoma, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3297	Osteoid Osteoma	A small, benign bone-forming neoplasm that can arise from any bone but more frequently affects the long bones. The central portion of the neoplasm (nidus) contains differentiated osteoblasts that produce osteoid and sometimes bone. The lesion is usually surrounded by hypervascular sclerotic bone and has limited growth potential. Clinical signs and symptoms include pain and localized tenderness, at the site of the lesion. The pain may be intense but in the majority of cases it is completely alleviated by non-steroidal anti-inflammatory drugs. Prognosis is excellent and recurrences are rare.	9191/0 | morphology || Osteoid osteoma, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3764	Adenomatous Polyp	A polypoid neoplasm that arises from the glandular epithelium of the gastrointestinal tract. There is a proliferation of glandular cells that may display dysplastic cytologic features. Representative examples include the adenomatous polyps of the colon and rectum.	8210/0 | morphology || Adenomatous polyp, NOS | primary_diagnosis || Polypoid adenoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3770	Pancreatic Neuroendocrine Carcinoma	An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the islet cells of the pancreas. The mitotic count is more than 20 per 10 HPF. It is classified as either small or large cell neuroendocrine carcinoma based on the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm.	8150/3 | morphology || Islet cell adenocarcinoma | primary_diagnosis || Islet cell carcinoma | primary_diagnosis || Pancreatic endocrine tumor, malignant | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3780	Large Cell Carcinoma	A carcinoma that is composed of malignant large epithelial cells. This category includes large cell undifferentiated carcinomas, large cell differentiated carcinomas including large cell neuroendocrine carcinomas, and giant cell carcinomas.	8012/3 | morphology || Large cell carcinoma, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3789	Olfactory Neuroblastoma	A rare neuroectodermal tumor originating from olfactory receptor cells in the sinonasal tract. In rare cases, it can be ectopic and originate from other sites such as the sellar region. Microscopically, it is characterized by neuroblastic differentiation with occasional formation of rosettes. If the tumor is not resected at an early stage, the prognosis is usually poor.	9522/3 | morphology || 9523/3 | morphology || Esthesioneuroblastoma | primary_diagnosis || Esthesioneuroepithelioma | primary_diagnosis || Olfactory neuroblastoma | primary_diagnosis || Olfactory neuroepithelioma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3801	Hemangioblastoma	A rare, highly vascular tumor that is composed of abundant capillaries and stromal cells. It arises from the central nervous system and infrequently other sites. It is a slow growing tumor with a low risk of metastasis, despite its benign histological features.	9161/1 | morphology || Angioblastoma | primary_diagnosis || Haemangioblastoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3803	Blue Nevus	A nevus characterized by the presence of benign pigmented dendritic spindle-shaped melanocytes. It most frequently occurs in the skin of the distal upper extremities, followed by the lower extremities, scalp, face, and buttocks. Extracutaneous presentations including in the conjunctiva, may also occur, but they are rare.	8780/0 | morphology || Blue nevus, NOS | primary_diagnosis || Jadassohn blue nevus | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C38661	Composite Lymphoma	Coexistence of Hodgkin and non-Hodgkin lymphoma in the same anatomic site.	9596/3 | morphology || Composite Hodgkin and non-Hodgkin lymphoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4134	Adenocarcinoma in Adenomatous Polyposis Coli	Adenocarcinomas that develop in colorectal adenomas in patients with a history of adenomatous polyposis coli. The mean age of development of adenocarcinoma is about 40 years.	8220/3 | morphology || Adenocarcinoma in adenomatous polyposis coli | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4136	Adenocarcinoma in Multiple Adenomatous Polyps	Adenocarcinomas that develop in gastrointestinal tract adenomas in patients with multiple adenomatous polyps.	8221/3 | morphology || Adenocarcinoma in multiple adenomatous polyps | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4141	Adenocarcinoma in Villous Adenoma	An adenocarcinoma that arises from a villous adenoma.	8261/3 | morphology || Adenocarcinoma in villous adenoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4144	Adenocarcinoma In Situ in Tubulovillous Adenoma	An intramucosal adenocarcinoma that arises from a tubulovillous adenoma.	8263/2 | morphology || Adenocarcinoma in situ in tubulovillous adenoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4145	Adenocarcinoma in Tubulovillous Adenoma	An adenocarcinoma that arises from a tubulovillous adenoma.	8263/3 | morphology || Adenocarcinoma in tubolovillous adenoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C41844	Regional Disease	A disease or condition that extends beyond the site of origin and spreads into adjacent tissues and regional lymph nodes.	Regional | progression_or_recurrence_type	C177640	progression_or_recurrence_type
C	C177537	GDC Value Terminology	C4222	Glomuvenous Malformation	A glomus tumor characterized by the presence of dilated veins, surrounded by small clusters of glomus cells.	8712/0 | morphology || Glomangioma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C43234	Not Reported	Not provided or available.	Not Reported | adapter_content || Not Reported | adrenal_hormone || Not Reported | adverse_event || Not Reported | adverse_event_grade || Not Reported | ajcc_clinical_m || Not Reported | ajcc_clinical_n || Not Reported | ajcc_clinical_stage || Not Reported | ajcc_clinical_t || Not Reported | ajcc_pathologic_m || Not Reported | ajcc_pathologic_n || Not Reported | ajcc_pathologic_stage || Not Reported | ajcc_pathologic_t || Not Reported | ajcc_staging_system_edition || Not Reported | alcohol_frequency || Not Reported | alcohol_history || Not Reported | alcohol_intensity || Not Reported | alcohol_type || Not Reported | anaplasia_present || Not Reported | anaplasia_present_type || Not Reported | aneuploidy || Not Reported | ann_arbor_b_symptoms || Not Reported | ann_arbor_b_symptoms_described || Not Reported | ann_arbor_clinical_stage || Not Reported | ann_arbor_extranodal_involvement || Not Reported | ann_arbor_pathologic_stage || Not Reported | antigen || Not Reported | asbestos_exposure_type || Not Reported | barretts_esophagus_goblet_cells_present || Not Reported | basic_statistics || Not Reported | best_overall_response || Not Reported | biospecimen_anatomic_site || Not Reported | biospecimen_laterality || Not Reported | biospecimen_type || Not Reported | bone_marrow_malignant_cells || Not Reported | burkitt_lymphoma_clinical_variant || Not Reported | calgb_risk_group || Not Reported | cancer_detection_method || Not Reported | cause_of_death || Not Reported | cause_of_death_source || Not Reported | cdc_hiv_risk_factors || Not Reported | chemical_exposure_type || Not Reported | chemo_concurrent_to_radiation || Not Reported | child_pugh_classification || Not Reported | chromosomal_translocation || Not Reported | chromosome || Not Reported | chromosome_arm || Not Reported | clark_level || Not Reported | clinical_trial_indicator || Not Reported | clonality || Not Reported | cog_liver_stage || Not Reported | cog_neuroblastoma_risk_group || Not Reported | cog_renal_stage || Not Reported | cog_rhabdomyosarcoma_risk_group || Not Reported | columnar_mucosa_present || Not Reported | comorbidities || Not Reported | comorbidity_method_of_diagnosis || Not Reported | consistent_pathology_review || Not Reported | contiguous_organ_invaded || Not Reported | country_of_birth || Not Reported | country_of_residence_at_enrollment || Not Reported | diabetes_treatment_type || Not Reported | diagnosis_pathologically_confirmed || Not Reported | disease_response || Not Reported | disease_type || Not Reported | distance_normal_to_tumor || Not Reported | double_expressor_lymphoma || Not Reported | double_hit_lymphoma || Not Reported | drug_category || Not Reported | dysplasia_degree || Not Reported | dysplasia_type || Not Reported | ecog_performance_status || Not Reported | education_level || Not Reported | eln_risk_classification || Not Reported | embolic_agent || Not Reported | enneking_msts_grade || Not Reported | enneking_msts_metastasis || Not Reported | enneking_msts_stage || Not Reported | enneking_msts_tumor_site || Not Reported | ensat_clinical_m || Not Reported | ensat_pathologic_n || Not Reported | ensat_pathologic_stage || Not Reported | ensat_pathologic_t || Not Reported | environmental_tobacco_smoke_exposure || Not Reported | esophageal_columnar_dysplasia_degree || Not Reported | esophageal_columnar_metaplasia_present || Not Reported | evidence_of_progression_type || Not Reported | evidence_of_recurrence_type || Not Reported | exposure_duration || Not Reported | exposure_source || Not Reported | exposure_type || Not Reported | extracapsular_extension || Not Reported | extracapsular_extension_present || Not Reported | extranodal_extension || Not Reported | extrathyroid_extension || Not Reported | eye_color || Not Reported | figo_stage || Not Reported | first_event || Not Reported | first_symptom_prior_to_diagnosis || Not Reported | gastric_esophageal_junction_involvement || Not Reported | gene_symbol || Not Reported | gleason_grade_group || Not Reported | gleason_grade_tertiary || Not Reported | goblet_cells_columnar_mucosa_present || Not Reported | haart_treatment_indicator || Not Reported | hepatitis_sustained_virological_response || Not Reported | histologic_progression_type || Not Reported | histone_family || Not Reported | histone_variant || Not Reported | history_of_tumor || Not Reported | history_of_tumor_type || Not Reported | hormonal_contraceptive_type || Not Reported | hormonal_contraceptive_use || Not Reported | hormonal_replacement_therapy_status || Not Reported | hormone_replacement_therapy_type || Not Reported | hpv_strain || Not Reported | hysterectomy_margins_involved || Not Reported | hysterectomy_type || Not Reported | igcccg_stage || Not Reported | imaging_anatomic_site || Not Reported | imaging_findings || Not Reported | imaging_result || Not Reported | imaging_type || Not Reported | immunosuppressive_treatment_type || Not Reported | initial_disease_status || Not Reported | inpc_grade || Not Reported | inpc_histologic_group || Not Reported | inrg_stage || Not Reported | inss_stage || Not Reported | instrument_model || Not Reported | international_prognostic_index || Not Reported | irs_group || Not Reported | irs_stage || Not Reported | ishak_fibrosis_score || Not Reported | iss_stage || Not Reported | karnofsky_performance_status || Not Reported | kmer_content || Not Reported | laboratory_test || Not Reported | largest_extrapelvic_peritoneal_focus || Not Reported | laterality || Not Reported | lymph_node_dissection_site || Not Reported | lymph_node_involved_site || Not Reported | lymph_node_involvement || Not Reported | lymph_nodes_removed || Not Reported | lymphatic_invasion_present || Not Reported | margin_status || Not Reported | margins_involved_site || Not Reported | marital_status || Not Reported | masaoka_stage || Not Reported | measurement_type || Not Reported | measurement_unit || Not Reported | medulloblastoma_molecular_classification || Not Reported | melanoma_known_primary || Not Reported | menopause_status || Not Reported | metaplasia_present || Not Reported | metastasis_at_diagnosis || Not Reported | method_of_diagnosis || Not Reported | method_of_sample_procurement || Not Reported | micrometastasis_present || Not Reported | micropapillary_features || Not Reported | mismatch_repair_mutation || Not Reported | mitosis_karyorrhexis_index || Not Reported | molecular_analysis_method || Not Reported | molecular_consequence || Not Reported | morphologic_architectural_pattern || Not Reported | morphology || Not Reported | mutation_codon || Not Reported | necrosis_present || Not Reported | non_nodal_regional_disease || Not Reported | non_nodal_tumor_deposits || Not Reported | nononcologic_therapeutic_agents || Not Reported | normal_tumor_genotype_snp_match || Not Reported | number_of_pregnancies || Not Reported | occupation_type || Not Reported | ovarian_specimen_status || Not Reported | ovarian_surface_involvement || Not Reported | overrepresented_sequences || Not Reported | oxygen_use_indicator || Not Reported | oxygen_use_type || Not Reported | parent_with_radiation_exposure || Not Reported | pathogenicity || Not Reported | per_base_n_content || Not Reported | per_base_sequence_content || Not Reported | per_base_sequence_quality || Not Reported | per_sequence_gc_content || Not Reported | per_sequence_quality_score || Not Reported | per_tile_sequence_quality || Not Reported | perineural_invasion_present || Not Reported | peripancreatic_lymph_nodes_positive || Not Reported | peritoneal_fluid_cytological_status || Not Reported | peritoneal_washing_results || Not Reported | ploidy || Not Reported | prcc_type || Not Reported | pregnancy_outcome || Not Reported | pregnant_at_diagnosis || Not Reported | premature_at_birth || Not Reported | prescribed_dose_units || Not Reported | preservation_method || Not Reported | primary_diagnosis || Not Reported | primary_gleason_grade || Not Reported | primary_site || Not Reported | prior_treatment || Not Reported | procedures_performed || Not Reported | progression_or_recurrence || Not Reported | progression_or_recurrence_anatomic_site || Not Reported | progression_or_recurrence_type || Not Reported | radiosensitizing_agent || Not Reported | reason_treatment_ended || Not Reported | reason_treatment_not_given || Not Reported | reflux_treatment_type || Not Reported | relationship_primary_diagnosis || Not Reported | relationship_type || Not Reported | relative_deceased || Not Reported | relative_smoker || Not Reported | residual_disease || Not Reported | residual_tumor || Not Reported | residual_tumor_measurement || Not Reported | rhabdoid_present || Not Reported | risk_factor_method_of_diagnosis || Not Reported | risk_factor_treatment || Not Reported | risk_factors || Not Reported | route_of_administration || Not Reported | sarcomatoid_present || Not Reported | satellite_nodule_present || Not Reported | scan_tracer_used || Not Reported | second_gene_symbol || Not Reported | secondary_gleason_grade || Not Reported | secondhand_smoke_as_child || Not Reported | sequence_duplication_levels || Not Reported | sequence_length_distribution || Not Reported | site_of_resection_or_biopsy || Not Reported | sites_of_involvement || Not Reported | smoking_frequency || Not Reported | specimen_type || Not Reported | staining_intensity_scale || Not Reported | staining_intensity_value || Not Reported | supratentorial_localization || Not Reported | synchronous_malignancy || Not Reported | test_analyte_type || Not Reported | test_result || Not Reported | test_units || Not Reported | therapeutic_agents || Not Reported | therapeutic_levels_achieved || Not Reported | therapeutic_target_level || Not Reported | time_between_waking_and_first_smoke || Not Reported | timepoint_category || Not Reported | tissue_or_organ_of_origin || Not Reported | tissue_type || Not Reported | tobacco_smoking_status || Not Reported | transglottic_extension || Not Reported | treatment_anatomic_sites || Not Reported | treatment_dose_units || Not Reported | treatment_effect || Not Reported | treatment_effect_indicator || Not Reported | treatment_emergent_adverse_event || Not Reported | treatment_frequency || Not Reported | treatment_intent_type || Not Reported | treatment_outcome || Not Reported | treatment_type || Not Reported | tumor_confined_to_organ_of_origin || Not Reported | tumor_depth_descriptor || Not Reported | tumor_descriptor || Not Reported | tumor_focality || Not Reported | tumor_grade || Not Reported | tumor_grade_category || Not Reported | tumor_infiltrating_lymphocytes || Not Reported | tumor_infiltrating_macrophages || Not Reported | tumor_regression_grade || Not Reported | tumor_shape || Not Reported | type_of_smoke_exposure || Not Reported | uicc_clinical_m || Not Reported | uicc_clinical_n || Not Reported | uicc_clinical_stage || Not Reported | uicc_clinical_t || Not Reported | uicc_pathologic_m || Not Reported | uicc_pathologic_n || Not Reported | uicc_pathologic_stage || Not Reported | uicc_pathologic_t || Not Reported | uicc_staging_system_edition || Not Reported | ulceration_indicator || Not Reported | undescended_testis_corrected || Not Reported | undescended_testis_corrected_laterality || Not Reported | undescended_testis_corrected_method || Not Reported | undescended_testis_history || Not Reported | undescended_testis_history_laterality || Not Reported | variant_origin || Not Reported | variant_type || Not Reported | vascular_invasion_present || Not Reported | vascular_invasion_type || Not Reported | viral_hepatitis_serology_tests || Not Reported | vital_status || Not Reported | weiss_assessment_findings || Not Reported | weiss_assessment_score || Not Reported | who_cns_grade || Not Reported | who_nte_grade || Not Reported | wilms_tumor_histologic_subtype || Not Reported | zone_of_origin_prostate || Not Reported | zygosity || not reported | classification_of_tumor || not reported | ethnicity || not reported | gender || not reported | last_known_disease_status || not reported | prior_malignancy || not reported | progression_or_recurrence || not reported | race || not reported | relationship_gender || not reported | relative_with_cancer_history || not reported | treatment_or_therapy || not reported | vital_status	C102562 || C102704 || C104014 || C104015 || C104017 || C104018 || C104023 || C104027 || C105721 || C106304 || C106317 || C106541 || C106551 || C111073 || C112400 || C121007 || C123560 || C125738 || C125904 || C126378 || C127762 || C127768 || C127772 || C129439 || C13202 || C133427 || C13355 || C133706 || C138899 || C139007 || C139577 || C140258 || C140259 || C140262 || C140266 || C141342 || C142346 || C143151 || C15256 || C154881 || C15599 || C156421 || C156422 || C157103 || C157110 || C157233 || C157410 || C157425 || C157437 || C158874 || C159229 || C159643 || C160720 || C160827 || C160837 || C160996 || C16124 || C161320 || C16165 || C162221 || C164057 || C16457 || C164683 || C16564 || C166199 || C166229 || C166276 || C16687 || C168796 || C17001 || C17049 || C17103 || C171253 || C17140 || C171435 || C173263 || C173544 || C17357 || C173595 || C17369 || C174459 || C175524 || C176287 || C176708 || C176985 || C177549 || C177550 || C177555 || C177556 || C177557 || C177558 || C177559 || C177561 || C177562 || C177564 || C177565 || C177566 || C177567 || C177568 || C177569 || C177570 || C177571 || C177572 || C177576 || C177577 || C177578 || C177579 || C177585 || C177586 || C177587 || C177588 || C177589 || C177590 || C177591 || C177592 || C177593 || C177594 || C177595 || C177596 || C177597 || C177598 || C177599 || C177600 || C177601 || C177602 || C177603 || C177604 || C177605 || C177606 || C177607 || C177608 || C177609 || C177610 || C177611 || C177612 || C177616 || C177617 || C177619 || C177620 || C177621 || C177622 || C177624 || C177626 || C177627 || C177628 || C177630 || C177631 || C177632 || C177633 || C177634 || C177635 || C177636 || C177637 || C177638 || C177640 || C177641 || C178243 || C178276 || C178286 || C178287 || C178288 || C178289 || C17953 || C181720 || C181723 || C182060 || C182097 || C182099 || C182101 || C182102 || C182109 || C182312 || C18304 || C185074 || C185264 || C185265 || C185266 || C185267 || C185268 || C185269 || C185270 || C185271 || C185272 || C185273 || C185274 || C185275 || C188000 || C188372 || C188373 || C188387 || C188388 || C188406 || C188408 || C188409 || C188411 || C188415 || C188429 || C188446 || C188448 || C188452 || C18849 || C18919 || C1909 || C19232 || C19697 || C19770 || C19796 || C198091 || C198092 || C198095 || C198101 || C198107 || C198127 || C198131 || C198139 || C198194 || C198195 || C198198 || C198200 || C198201 || C198204 || C198206 || C199145 || C200441 || C200442 || C200444 || C200446 || C200469 || C200473 || C200474 || C200476 || C200477 || C20118 || C202137 || C202138 || C202139 || C202140 || C202155 || C202157 || C202158 || C202159 || C202160 || C206478 || C206479 || C206480 || C2480 || C25185 || C25188 || C25193 || C25218 || C25294 || C25717 || C268 || C28013 || C28076 || C2873 || C29878 || C2991 || C33027 || C3420 || C35529 || C35886 || C36037 || C36292 || C38032 || C38114 || C39694 || C4086 || C41331 || C42578 || C43283 || C45824 || C45902 || C4809 || C48603 || C48604 || C48605 || C49236 || C50995 || C54398 || C574 || C67415 || C70700 || C70713 || C70729 || C81180 || C81229 || C81239 || C83280 || C83315 || C83393 || C85416 || C89081 || C90491 || C92808 || C93431 || C93711 || C94536 || C94811 || C95149 || C97229 || C97926 || C99532	inpc_grade || reason_treatment_not_given || weiss_assessment_score || weiss_assessment_findings || ensat_pathologic_stage || ensat_pathologic_t || ensat_pathologic_n || ensat_clinical_m || ecog_performance_status || tumor_regression_grade || mitosis_karyorrhexis_index || menopause_status || number_of_pregnancies || igcccg_stage || premature_at_birth || child_pugh_classification || margin_status || figo_stage || double_hit_lymphoma || alcohol_intensity || staining_intensity_value || perineural_invasion_present || vascular_invasion_present || medulloblastoma_molecular_classification || chromosome || inrg_stage || chromosome_arm || mismatch_repair_mutation || double_expressor_lymphoma || iss_stage || residual_tumor || enneking_msts_stage || enneking_msts_grade || enneking_msts_tumor_site || enneking_msts_metastasis || chemo_concurrent_to_radiation || gleason_grade_group || masaoka_stage || hysterectomy_type || ulceration_indicator || hormone_replacement_therapy_type || site_of_resection_or_biopsy || tissue_or_organ_of_origin || exposure_type || hpv_strain || first_symptom_prior_to_diagnosis || hormonal_contraceptive_use || tumor_focality || eye_color || primary_site || calgb_risk_group || lymph_nodes_removed || lymphatic_invasion_present || satellite_nodule_present || extranodal_extension || transglottic_extension || prior_treatment || synchronous_malignancy || haart_treatment_indicator || metastasis_at_diagnosis || type_of_smoke_exposure || comorbidities || treatment_emergent_adverse_event || ethnicity || treatment_dose_units || tumor_descriptor || reason_treatment_ended || histone_family || pathogenicity || ploidy || race || risk_factors || second_gene_symbol || environmental_tobacco_smoke_exposure || biospecimen_anatomic_site || sites_of_involvement || variant_type || gender || gene_symbol || imaging_type || classification_of_tumor || peritoneal_fluid_cytological_status || cause_of_death_source || imaging_result || morphology || irs_group || irs_stage || ajcc_clinical_stage || ajcc_pathologic_stage || test_analyte_type || ann_arbor_clinical_stage || ann_arbor_pathologic_stage || ajcc_staging_system_edition || eln_risk_classification || comorbidity_method_of_diagnosis || inpc_histologic_group || who_cns_grade || who_nte_grade || wilms_tumor_histologic_subtype || margins_involved_site || progression_or_recurrence_anatomic_site || supratentorial_localization || distance_normal_to_tumor || method_of_diagnosis || evidence_of_recurrence_type || dysplasia_degree || country_of_residence_at_enrollment || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || burkitt_lymphoma_clinical_variant || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || hysterectomy_margins_involved || metaplasia_present || necrosis_present || non_nodal_regional_disease || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || ovarian_surface_involvement || progression_or_recurrence || rhabdoid_present || risk_factor_treatment || variant_origin || biospecimen_laterality || ajcc_clinical_m || ajcc_pathologic_m || ovarian_specimen_status || viral_hepatitis_serology_tests || instrument_model || ajcc_clinical_n || ajcc_pathologic_n || initial_disease_status || last_known_disease_status || pregnant_at_diagnosis || histone_variant || primary_diagnosis || relationship_gender || cdc_hiv_risk_factors || secondhand_smoke_as_child || smoking_frequency || time_between_waking_and_first_smoke || cog_liver_stage || cog_neuroblastoma_risk_group || cog_renal_stage || cog_rhabdomyosarcoma_risk_group || hepatitis_sustained_virological_response || ajcc_clinical_t || ajcc_pathologic_t || reflux_treatment_type || treatment_effect_indicator || progression_or_recurrence_type || esophageal_columnar_dysplasia_degree || relationship_primary_diagnosis || peripancreatic_lymph_nodes_positive || anaplasia_present || anaplasia_present_type || vascular_invasion_type || largest_extrapelvic_peritoneal_focus || education_level || consistent_pathology_review || undescended_testis_corrected_laterality || parent_with_radiation_exposure || undescended_testis_corrected || undescended_testis_history || undescended_testis_corrected_method || undescended_testis_history_laterality || adrenal_hormone || imaging_anatomic_site || clonality || history_of_tumor_type || adapter_content || basic_statistics || kmer_content || overrepresented_sequences || per_base_n_content || per_base_sequence_content || per_base_sequence_quality || per_sequence_gc_content || per_sequence_quality_score || per_tile_sequence_quality || sequence_duplication_levels || sequence_length_distribution || alcohol_frequency || exposure_source || asbestos_exposure_type || clinical_trial_indicator || drug_category || uicc_clinical_m || uicc_clinical_n || uicc_clinical_stage || uicc_clinical_t || uicc_pathologic_m || uicc_pathologic_n || uicc_pathologic_stage || uicc_pathologic_t || zone_of_origin_prostate || history_of_tumor || prior_malignancy || treatment_outcome || therapeutic_agents || preservation_method || tissue_type || molecular_analysis_method || tobacco_smoking_status || cancer_detection_method || chemical_exposure_type || evidence_of_progression_type || extracapsular_extension || first_event || lymph_node_dissection_site || mutation_codon || peritoneal_washing_results || residual_tumor_measurement || risk_factor_method_of_diagnosis || therapeutic_levels_achieved || therapeutic_target_level || timepoint_category || tumor_grade_category || uicc_staging_system_edition || imaging_findings || country_of_birth || contiguous_organ_invaded || measurement_type || melanoma_known_primary || relative_smoker || tumor_depth_descriptor || tumor_shape || tumor_infiltrating_lymphocytes || tumor_infiltrating_macrophages || international_prognostic_index || extracapsular_extension_present || extrathyroid_extension || histologic_progression_type || micrometastasis_present || nononcologic_therapeutic_agents || oxygen_use_indicator || oxygen_use_type || radiosensitizing_agent || staining_intensity_scale || prescribed_dose_units || hormonal_replacement_therapy_status || prcc_type || scan_tracer_used || laterality || marital_status || occupation_type || treatment_type || laboratory_test || vital_status || antigen || karnofsky_performance_status || tumor_grade || aneuploidy || relative_with_cancer_history || disease_type || lymph_node_involved_site || chromosomal_lymph_node_involvement || morphologic_architectural_pattern || tumor_confined_to_organ_of_origin || test_result || treatment_effect || route_of_administration || sarcomatoid_present || dysplasia_type || adverse_event || measurement_unit || ann_arbor_b_symptoms_described || zygosity || alcohol_type || residual_disease || primary_gleason_grade || secondary_gleason_grade || gleason_grade_tertiary || treatment_or_therapy || disease_response || treatment_intent_type || immunosuppressive_treatment_type || test_units || method_of_sample_procurement || specimen_type || treatment_anatomic_sites || relative_deceased || alcohol_history || cause_of_death || exposure_duration || biospecimen_type || relationship_type || inss_stage || treatment_frequency || pregnancy_outcome || hormonal_contraceptive_type || procedures_performed || adverse_event_grade || best_overall_response || clark_level || ishak_fibrosis_score || embolic_agent || molecular_consequence || diabetes_treatment_type
C	C177537	GDC Value Terminology	C43352	Brooke-Spiegler Syndrome	A rare autosomal dominant genodermatosis associated with germline mutations of the CYLD tumor suppressor gene. It is characterized by the development of multiple adnexal tumors (usually cylindromas and trichoepitheliomas), typically in the skin of the scalp. It manifests with numerous papules and/or large dome-shaped nodules on the scalp, resembling a turban.	8200/0 | morphology || Turban tumor | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C43565	Appendix Tubular Neuroendocrine Tumor	A neuroendocrine tumor that arises from the appendix.  It does not show the morphologic characteristics of typical carcinoid tumors (neoplastic cells forming solid nests). In contrast, the tumor cells form small discrete tubules.	8245/1 | morphology || Tubular carcinoid | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C43625	Hepatocellular Pleomorphic Carcinoma	A morphologic variant of hepatocellular carcinoma, characterized by the presence of malignant cells which show marked variation in their size and shape. Bizarre mononuclear or multinucleated giant cells are often present.	8175/3 | morphology || Hepatocellular carcinoma, pleomorphic type | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C43627	Hepatocellular Sarcomatoid Carcinoma	A morphologic variant of hepatocellular carcinoma characterized by the presence of malignant spindle cells or atypical giant cells.	8173/3 | morphology || Hepatocellular carcinoma, sarcomatoid | primary_diagnosis || Hepatocellular carcinoma, spindle cell variant | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C45837	Non-Functioning Pancreatic Neuroendocrine Tumor	A well-differentiated, low-, intermediate-, or high-grade neoplasm with neuroendocrine differentiation that arises from the pancreas.  It is characterized by the absence of a hormone-related clinical syndrome.	Pancreatic endocrine tumor, nonfunctioning | primary_diagnosis	C177621	primary_diagnosis
C	C177537	GDC Value Terminology	C45967	Extensible Markup Language	A general-purpose markup language for creating special-purpose markup languages. It is capable of describing many different kinds of data. Its primary purpose is to facilitate the sharing of data across different systems, particularly systems connected via the Internet.	XML | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C47845	FASTA Format	A text-based format for representing either nucleotide sequences or peptide sequences. It consists of a single-line description, followed by lines of sequence data.  Sequences are represented in the standard IUPAC-IUB (International Union of Pure and Applied Chemistry-International Union of Biochemistry Commission on Biochemical Nomenclature) single letter amino acid and nucleic acid base codes. It is an extension of the FAST-P (protein) and FAST-N (nucleotide) alignment tools.	FASTA | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C4809	Residual Disease	The persistence of tumor cells in the body following cancer treatment.	Residual Disease | initial_disease_status	C177616	initial_disease_status
C	C177537	GDC Value Terminology	C48230	JPEG	A file compression format mostly used for color and greyscale photographs.	JPEG | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C4973	Perineurioma	A rare, usually benign tumor composed entirely of neoplastic perineurial cells. It may occur in the soft tissues, intraneurally, or in mucosal sites.	9571/0 | morphology || Perineurioma, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C5754	Hepatocellular Clear Cell Carcinoma	A morphologic variant of hepatocellular carcinoma characterized by the presence of clear cells.	8174/3 | morphology || Hepatocellular carcinoma, clear cell type | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C63622	Undifferentiated Carcinoma with Osteoclast-Like Giant Cells	A usually aggressive carcinoma composed of malignant cells that do not display evidence of glandular or squamous differentiation, and giant cells resembling osteoclasts.	8035/3 | morphology || Carcinoma with osteoclast-like giant cells | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C63805	Portable Document Format	An open file format created and controlled by Adobe Systems, for representing two-dimensional documents in a device independent and resolution independent fixed-layout document format. Each PDF file encapsulates a complete description of a 2D document that includes the text, fonts, images, and 2D vector graphics that compose the document. PDF files do not encode information that is specific to the application software, hardware, or operating system used to create or view the document. This feature ensures that a valid PDF will render exactly the same regardless of its origin or destination (but depending on font availability when fonts are not encapsulated in the file).	PDF | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C6846	Thyroid Gland Hyalinizing Trabecular Tumor	A rare, circumscribed or encapsulated tumor arising from the follicular cells of the thyroid gland.  It is characterized by a trabecular growth pattern and hyalinized stroma formation.  The vast majority of cases have a benign clinical course.	8190/0 | morphology || 8336/0 | morphology || Hyalinizing trabecular adenoma | primary_diagnosis || Trabecular adenoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C7018	Nerve Sheath Myxoma	A benign neoplasm with nerve sheath features that usually arises from the dermis and subcutaneous tissue. It is composed of spindle and epithelioid cells in a myxoid stroma.	9562/0 | morphology || Nerve sheath myxoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C70543	Never	Not ever; at no time (in the past or future).	Never | treatment_frequency	C89081	treatment_frequency
C	C177537	GDC Value Terminology	C70631	TIFF	A bitmap graphics file format utilizing tagged fields.	TIFF | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C7072	Oncocytic Neoplasm	A usually benign neoplasm composed of large cells with abundant eosinophilic granular cytoplasm.	Oncocytoma | primary_diagnosis	C177621	primary_diagnosis
C	C177537	GDC Value Terminology	C72074	Neuroendocrine Tumor G2	A well-differentiated, intermediate-grade epithelial neoplasm with neuroendocrine differentiation. It usually arises from the digestive system, lung, and head and neck.	8249/3 | morphology || Atypical carcinoid tumor | primary_diagnosis || G2 | who_nte_grade || Neuroendocrine tumor, grade 2 | primary_diagnosis	C176985 || C177567 || C177621	morphology || who_nte_grade || primary_diagnosis
C	C177537	GDC Value Terminology	C74084	Nelitolimod	A class C CpG-oligodeoxynucleotide (ODN) agonist of toll-like receptor 9 (TLR9), with immunostimulatory, immunoadjuvant and antineoplastic activities. Upon administration, nelitolimod targets, binds to and activates TLR9 expressed on plasmacytoid dendritic cells (DCs), natural killer cells (NKs) and B-cells. This initiates cytokine release from DCs and activates innate immune signaling pathways, and leads to the activation of a cytotoxic T-lymphocyte (CTL)-mediated immune response against antigens expressed by the tumor cells. TLR9, a member of the TLR family, plays a fundamental role in pathogen recognition and activation of the innate immune system.	TLR9 Agonist SD-101 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C7676	Adenocarcinoma in Adenomatous Polyp	An adenocarcinoma that arises from an adenomatous polyp.	8210/3 | morphology || Adenocarcinoma in a polyp, NOS | primary_diagnosis || Adenocarcinoma in adenomatous polyp | primary_diagnosis || Adenocarcinoma in polypoid adenoma | primary_diagnosis || Carcinoma in adenomatous polyp | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C7677	Adenocarcinoma in Tubular Adenoma	An adenocarcinoma that arises from a tubular adenoma.	8210/3 | morphology || Adenocarcinoma in tubular adenoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C7678	Adenocarcinoma In Situ in Adenomatous Polyp	An intramucosal adenocarcinoma that arises from an adenomatous polyp.	8210/2 | morphology || Adenocarcinoma in situ in a polyp, NOS | primary_diagnosis || Adenocarcinoma in situ in adenomatous polyp | primary_diagnosis || Adenocarcinoma in situ in polypoid adenoma | primary_diagnosis || Carcinoma in situ in a polyp, NOS | primary_diagnosis || Carcinoma in situ in adenomatous polyp | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C7679	Adenocarcinoma In Situ in Tubular Adenoma	An intramucosal adenocarcinoma that arises from a tubular adenoma.	8210/2 | morphology || Adenocarcinoma in situ in tubular adenoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C82937	MAGE-TAB	A tab-delimited, spreadsheet-based format that can be used for annotating and communicating microarray data with experimental details in a MIAME (Minimum Information About a Microarray Experiment) compliant fashion.	MAGE-TAB | data_format || MAGETAB | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C8376	Adenocarcinoma In Situ in Villous Adenoma	An intramucosal adenocarcinoma that arises from a villous adenoma.	8261/2 | morphology || Adenocarcinoma in situ in villous adenoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C85873	Plain Text Data Format	A data format consisting of readable textual material maintained as a sequential file.	TXT | data_format	C171252	data_format
C	C177537	GDC Value Terminology	C88337	Topical Sonidegib	A topical formulation containing sonidegib, a small-molecule Smoothened (Smo) antagonist, with potential antineoplastic activity. Upon topical application, sonidegib selectively binds to the Hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway and, so, the inhibition of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Inappropriate activation of Hh pathway signaling and uncontrolled cellular proliferation, as is observed in a variety of cancers, may be associated with mutations in the Hh-ligand cell surface receptor Smo.	Smoothened Antagonist LDE225 Topical | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C8975	Female Reproductive System Carcinosarcoma	An aggressive malignant tumor of the female reproductive system, affecting predominantly elderly menopausal women.  The endometrium and ovary are the most common sites of tumor origin.  Morphologically, it is a high grade tumor, composed of carcinomatous and sarcomatous elements.	8981/3 | morphology || Carcinosarcoma, embryonal | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C9291	Anal Carcinoma	A carcinoma that arises from the anal canal or perianal area (anal margin). Histologic types include squamous cell carcinoma and adenocarcinoma.	Anal Cancer (all types) | tumor_code	C177615	tumor_code
C	C177537	GDC Value Terminology	C96025	pTa TNM Finding	A term that refers to a TNM finding of a primary, non-invasive papillary carcinoma.	Ta | ajcc_clinical_t || Ta | ajcc_pathologic_t || Ta | uicc_clinical_t || Ta | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t